1 Pincus T. The underestimated long-term medical and economic consequences of RA. Drugs 1995;50(suppl I):1-14
2 Maini RN, Taylor P.C, Anti-cytokine therapy for rheumatoid arthritis. Annu. Rev. Med 2000; 51:207-229
3Feldmann M, Brennan RM, Maini R.N. Role of cytokines in rheumatoid arthritis. Ann. Rev. Immunol. 1996;14:397-440
4 McInnes IB Leung B,Liew F.Y. Cell-cell interactions in synovitis: Interactions between T lymphocytes and synovial cells. Arthritis Res;2000.2:374-78.
5 Scott DTL, Shipley M, Dawson A et al. The clinical management of rheumatoid arthritis and osteoarthritis: Strategies for improving clinical effectiveness. Br J Rheum 1998;37:546-54
6 Fuchs HA, Kaye JJ, Callahan LF et al. Evidence of significant radiographic damage in RA within the first 2 years of disease. J Rheurnatol 1989;16:585-591
7 Fuchs HA, Pincus T. Radiographic damage in RA: description by non-linear models. J Rheumatol 1992;19:1655-58
8 Egesmose C, Lund B, Borg G et al. Patients with rheumatoid arthritis benefit from early second line treatment: 5-year follow-up of a prospective double blind placebo controlled study. J Rheumatol 1995;22:2208-13
9 Munro R, Hampson R, McEntegert A, Thomson EA, Madhok R, Capell HA. Improved functional outcome in patients with early rheumatoid arthritis treated with intramuscular gold: Results of a 5 year prospective study. Ann Rheum Dis 1998;57(2):88-93
10 Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M (for the ATTRACT group). Infliximab (chimeric anti-tumour necrosis factor monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 1999;354:1932-39
11 Weinblatt ME, Kremer JM, Bankliurst AD, Bulpitt KJ, Fleischmann RM, Fox RK, Jackson CG et al. A trial of etanercept, a recombinant Tumour Necrosis Factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. NEJM 1999;340(4):253-59
12 O’Dell JR, Haire CE, Erikson N, Drymalski W, Palmer W, Eckhoff P et al. Treatment of rheumatoid arthritis with methotrexate alone, sulphasalazine and hydroxychloroquine or a combination of all 3 medications. NEJM 1996;334(20):1287-1291
13 Weinblatt ME, Kremer JM, Coblyn JS, Maier AL, Helfgott SM, Morrell M. Pharmacokinetics, safety and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum 1999;42(7):1322-28
14 Tugwell P, Pincus T, Yocum D, Stein M, Gluck 0, Kraag G et al. Combination treatment with cyclosporin A and methotrexate in severe rheumatoid arthritis. New Engl J Med 1995;333(3):137-141.
15 O’Dell, Leff R, Paulson G, Haire C, Mallek J, Eckhoff PJ et al. Methotrexate (M)hydroxychloroquine H Sulphasalazine (S) versus M-H or M-S for rheumatoid arthritis (RA): Results of a double blind study. Arthritis Rheum 1999;42(9 suppl): S 117, abs 282
16 Bathon JM, Martin R.W, Roy M et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586-93
17 McFarlane AC, Brooks PM. An analysis of the relationship between psychological morbidity and disease activity in rheumatoid arthritis. J Rheumatol 1988; 15:928-31
18 McEntegert A, Morrison E, Capell HA, Duncan MR, Porter D, Madhok R, Thomson EA. The effect of social deprivation on disease severity and outcome in patients with RA. Ann Rheum Dis 1997;56:410-413.
19 Young A, Williams P, Dixey J, Cox N, Davies P, DevIin J et al. How many patients with early rheumatoid arthritis are likely to need TNF alpha blocking drugs? Results from a prospective study of 926 patients over 5 years. Arthritis Rheum 2000;43(suppl):227 abs 965
20 Felson DT, Anderson JJ, Meenan RF. Use of short term efficacy/toxicity trade offs to select second line drugs in RA. A metaanalysis of published clinical trials. Arthritis Rheum 1992;35(10):1117-1125
21 Kraan MC, Versendaal H, Jonker M, Bresnihan B, Post WJ, Hart BA et al. Asymptomatic synovitis precedes clinically manifest arthritis. Arthritis Rheum 1998;41(8):1481-88
22 Smolen JS, Breedveld FC, Burinester GR, Combe B, Emery P, Kalden JR et al Consensus statement on the initiation and continuation of tumour necrosis factor blocking therapies in rheumatoid arthritis. Ann Rheum Dis 2000;59:504-505
23 Gershon S, Wise RP, Nui M, Rockville JS. Post licensure reports of infection during use of etanercept and infliximab. Arthritis Rheum 2000;43: Late breaking abstract.
24 Perez T, Remy-Jardin M, Corlet B. Airways involvement in rheumatoid arthritis: clinical, functional and HRCT findings. Am J Resp and Crit Care Med 1998;157:1658-65
25 Charles PJ, Smeenk R.LT, De Jong J, Feldmann M, Maini R.N. Assessment of antibodies to double stranded DNA in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor a. Arthritis Rheum 2000; 43(11)2383-2390
26 Choi HK, Seeger JD, Kuntz KM. A cost effectiveness analysis of treatment options for patients with methotrexate resistant rheumatoid arthritis. Arthritis Rheum 2000;43(10):2316-2327
27 Krause D, Schleusser B, Herborn G, Rau R. Response to methotrexate is associated with reduced mortality in patients with severe rheumatoid arthritis. Arthritis Rheum 2000;(43):1421
28 Lehtinen K, Isomaki H. Intramuscular Gold therapy is associated with long survival in patient with rheumatoid arthritis. J Rheumatol 1991; 18: 524-27